Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189345
Status:
COMPLETED
Last Update Posted:
2006-11-08
First Post:
2005-09-12
Brief Title:
Randomized Multicenter 2-Dose Level Open-Label Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody RemovabTM Anti-EpCAM x Anti-CD3 to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Sponsor:
Organization:
AGO Study Group